Last reviewed · How we verify
Paritaprevir/ritonavir/ombitasvir
Paritaprevir inhibits hepatitis C virus NS3/4A protease, while ritonavir boosts its levels, and ombitasvir inhibits the NS5A protein, together blocking viral replication.
Paritaprevir inhibits hepatitis C virus NS3/4A protease, while ritonavir boosts its levels, and ombitasvir inhibits the NS5A protein, together blocking viral replication. Used for Chronic hepatitis C virus infection (genotype 1, 4, 5, 6).
At a glance
| Generic name | Paritaprevir/ritonavir/ombitasvir |
|---|---|
| Also known as | Paritaprevir also known as ABT-450, Ombitasvir also known as ABT-267, Viekira Pak |
| Sponsor | AbbVie |
| Drug class | Hepatitis C virus protease inhibitor and NS5A inhibitor combination |
| Target | HCV NS3/4A protease; HCV NS5A protein |
| Modality | Small molecule |
| Therapeutic area | Virology/Hepatology |
| Phase | Phase 3 |
Mechanism of action
This is a fixed-dose combination targeting multiple steps of the hepatitis C virus lifecycle. Paritaprevir directly inhibits the NS3/4A serine protease required for viral polyprotein processing. Ritonavir acts as a pharmacokinetic booster, inhibiting CYP3A4 to increase paritaprevir exposure. Ombitasvir blocks the NS5A protein, which is essential for viral RNA replication and virion assembly.
Approved indications
- Chronic hepatitis C virus infection (genotype 1, 4, 5, 6)
Common side effects
- Fatigue
- Headache
- Nausea
- Pruritus
- Elevated bilirubin
Key clinical trials
- Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment (PHASE4)
- MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV (PHASE4)
- A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (PHASE3)
- Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P (PHASE3)
- A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (PHASE3)
- Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions
- The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects
- Study of Oral Treatments for Hepatitis C (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Paritaprevir/ritonavir/ombitasvir CI brief — competitive landscape report
- Paritaprevir/ritonavir/ombitasvir updates RSS · CI watch RSS
- AbbVie portfolio CI